Jennison Associates LLC Has $727,000 Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Jennison Associates LLC grew its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 26.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 23,848 shares of the company’s stock after purchasing an additional 4,949 shares during the period. Jennison Associates LLC’s holdings in Intellia Therapeutics were worth $727,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Blue Trust Inc. acquired a new stake in Intellia Therapeutics in the fourth quarter worth $26,000. Signaturefd LLC raised its holdings in shares of Intellia Therapeutics by 89.3% during the fourth quarter. Signaturefd LLC now owns 1,592 shares of the company’s stock worth $49,000 after acquiring an additional 751 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of Intellia Therapeutics by 95.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,263 shares of the company’s stock worth $72,000 after acquiring an additional 1,108 shares during the period. Daiwa Securities Group Inc. raised its holdings in shares of Intellia Therapeutics by 35.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 3,056 shares of the company’s stock worth $93,000 after acquiring an additional 793 shares during the period. Finally, Pathstone Family Office LLC raised its holdings in shares of Intellia Therapeutics by 20.3% during the third quarter. Pathstone Family Office LLC now owns 6,438 shares of the company’s stock worth $204,000 after acquiring an additional 1,086 shares during the period. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently commented on NTLA. Canaccord Genuity Group raised their price objective on shares of Intellia Therapeutics from $72.00 to $73.00 and gave the stock a “buy” rating in a report on Friday, February 23rd. Wolfe Research began coverage on shares of Intellia Therapeutics in a report on Thursday, February 15th. They set a “peer perform” rating on the stock. The Goldman Sachs Group lowered shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the company from $136.00 to $32.00 in a research note on Friday, February 23rd. Finally, Wedbush reiterated a “neutral” rating and issued a $29.00 price target on shares of Intellia Therapeutics in a research note on Tuesday, April 23rd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $67.00.

Intellia Therapeutics Price Performance

Shares of NTLA opened at $20.76 on Friday. The firm has a 50-day moving average of $26.51 and a 200-day moving average of $27.54. Intellia Therapeutics, Inc. has a one year low of $19.37 and a one year high of $47.48.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, February 22nd. The company reported ($1.46) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.01. The company had revenue of ($1.92) million during the quarter, compared to the consensus estimate of $15.10 million. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 43.91%. During the same quarter last year, the firm posted ($1.40) EPS. As a group, analysts expect that Intellia Therapeutics, Inc. will post -5.57 EPS for the current year.

Insider Buying and Selling

In related news, EVP James Basta sold 2,297 shares of Intellia Therapeutics stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $32.99, for a total transaction of $75,778.03. Following the completion of the sale, the executive vice president now owns 81,571 shares of the company’s stock, valued at approximately $2,691,027.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 3.00% of the stock is currently owned by insiders.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.